Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 66 Publications

13 Customer Reviews

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NHXpPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuxeHU4OiCq Mn7xSG1UVw>? NGHi[IlKSzVyPUCuNFAxODdizszN NHvQfnoyPzl3NkC4NC=>
K562 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe3NkBp MVvEUXNQ NITmRVNKSzVyPUCuNFAyKM7:TR?= NYHiR|BZOTd7NU[wPFA>
M07e NX7OVlB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe3NkBp MlrzSG1UVw>? M17BSGlEPTB;MD6wNFEzKM7:TR?= NIPmbG8yPzl3NkC4NC=>
ALL3 NUfWNFVkS3m2b4TvfIlkKEG|c3H5 M3jCU|AvOc7:TR?= MYe3NkBp NXTYTmlDTE2VTx?= MlfSTWM2OD1yLkCwNFQh|ryP MlLuNVk5QDl3NEC=
CML MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmyNEBucW5? MX;EUXNQ Mom0TWM2OD1yLkCwNUDPxE1? NH;XPXoyQTJzOUCxOi=>
BA/F3 NXu4fGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\2O|IhcA>? MVHEUXNQ MYTJR|UxRTZwNUi5JO69VQ>? NWDR[IEzOjNyOEi2OFQ>
BA/F3 M{SwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW3NkBp NELlO2tFVVOR NYH0dppZUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> Mlm2NlMxQDh4NES=
BA/F3 NXfkdlB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fvcVczKGh? NFPReXdFVVOR NV3OOlhsUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= Ml\6NlMxQDh4NES=
BA/F3 M1\HUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PiXFczKGh? NIPXUWJFVVOR MW\JcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1? M1HlWFI{ODh6NkS0
BA/F3 NVjMSZJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTCO|IhcA>? NInVVXdFVVOR M2[2bmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP MoH1NlM{ODF5MEO=
BA/F3 NV25ZYJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S0TlczKGh? M3z4bGROW09? MnOwTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1? M374XlI{OzBzN{Cz
BA/F3 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXKcI9xPzJiaB?= NUC2b4ltTE2VTx?= NUDrdWw5UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiR{K1NGUhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxPTIQvF2= MYOyN|MxOTdyMx?=
BA/F3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDTXIo4OiCq MoDhSG1UVw>? NVzrVZhmUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= NUf0UGh4OjN|MEG3NFM>
BA/F3 MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn4NW84OiCq MmfiSG1UVw>? M3PWOWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP MoHMNlM{ODF5MEO=
BA/F3 NEnDT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDDO|IhcA>? MX7EUXNQ NXvtW3NRUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1? NGDqNlczOzNyMUewNy=>
BA/F3 NFrXTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXkdW9xPzJiaB?= M4LlNWROW09? MUPJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? NH73bHYzOzNyMUewNy=>
BA/F3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\MOFBuPzJiaB?= NGXNSVRFVVOR NFrxTWRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? NX3oXJNSOjN|MEG3NFM>
BA/F3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPqO|IhcA>? M2LnWWROW09? NYHkUYwxUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN MXSyN|MxOTdyMx?=
T cell M4LPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXnO|IhcA>? NYLacmNnTE2VTx?= NYC0VWZwUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1? M16zRlE4OTV2NUGy
WiDr M3;zTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP2[XJGPzJiaB?= NFjVSndFVVOR NHjCfZBKSzVyPUCuNFUzKM7:TR?= MoPyNVU3OTV3MUK=
PC3 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XWdVczKGh? MYjEUXNQ NHzxSW5KSzVyPUCuNFA6PCEQvF2= MU[xOVYyPTVzMh?=
MDA-MB-231 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO3NkBp NXXlNWZHTE2VTx?= MlvjTWM2OD1yLkCxNkDPxE1? M4KwV|E2PjF3NUGy
Hs578T NXuyXI1pS3m2b4TvfIlkKEG|c3H5 MWm3NkBp Ml6zSG1UVw>? M{K2R2dKPTB;MD6wN{DPxE1? NEjsSZEzPDBzNUOyOy=>
HMEC NWXjNlhFS3m2b4TvfIlkKEG|c3H5 MmDlO|IhcA>? MlzqSG1UVw>? NYiwd4VZT0l3ME2xMlgh|ryP M4rmWVI1ODF3M{K3
DU145 NIPB[HVEgXSxdH;4bYMhSXO|YYm= Mk\6O|IhcA>? M1zm[2ROW09? M{\ENmdKPTB;MD6xOkDPxE1? MYWyOFAyPTN{Nx?=
U251 NFXtOm5EgXSxdH;4bYMhSXO|YYm= MXS3NkBp M{HHNWROW09? M1fP[GdKPTB;Mj64NUDPxE1? MWeyOFAyPTN{Nx?=
NCI60 MV7DfZRwfG:6aXOgRZN{[Xl? NX;Ud2k2PzJiaB?= NXLhR4NDTE2VTx?= M33HVmdKPTB;NT63JO69VQ>? NVjp[3prOjRyMUWzNlc>
MALME-3M MYjDfZRwfG:6aXOgRZN{[Xl? NWfPRY92PzJiaB?= M2nqTGROW09? MY\HTVUxRTZwNkGg{txO MoTPNlQxOTV|Mke=
KM12 MoDJR5l1d3SxeHnjJGF{e2G7 M1TMdlczKGh? MkXGSG1UVw>? MoG4S2k2OD15LkS0JO69VQ>? MW[yOFAyPTN{Nx?=
SW620 MoPNR5l1d3SxeHnjJGF{e2G7 M3\6[|czKGh? NV3XV4Q3TE2VTx?= MYDHTVUxRThwNEOg{txO M37VOFI1ODF3M{K3
RXF 393NL NULGSI84S3m2b4TvfIlkKEG|c3H5 MWG0JIRigXN? NV7wfHpTTE2VTx?= M4H3UWlEPTB;MD6wNlE4KM7:TR?= NX65c|RxOjN{NUOwO|Q>
LXFA 983L MX\DfZRwfG:6aXOgRZN{[Xl? M3qzSlQh\GG7cx?= M{X6NGROW09? NXvQfYlEUUN3ME2wMlA2PjVizszN MojpNlMzPTNyN{S=
PRXF DU145 Mo[4R5l1d3SxeHnjJGF{e2G7 NX34XFFLPCCmYYnz MkfhSG1UVw>? MUTJR|UxRTBwME[yN{DPxE1? NYPVTYtOOjN{NUOwO|Q>
PAXF 1657L MXPDfZRwfG:6aXOgRZN{[Xl? M{m5U|Qh\GG7cx?= NXfFOXJoTE2VTx?= MXzJR|UxRTBwMUKxJO69VQ>? MUmyN|I2OzB5NB?=
CXF 1103L MYHDfZRwfG:6aXOgRZN{[Xl? NXH2[YZWPCCmYYnz M2O2RmROW09? MoPWTWM2OD12LkO2JO69VQ>? NETtb2UzOzJ3M{C3OC=>
GXF251L NH;lboNEgXSxdH;4bYMhSXO|YYm= NIjOTGM1KGSjeYO= NVrBVI1qTE2VTx?= MoHCTWM2OD1{LkK1JO69VQ>? MV2yN|I2OzB5NB?=
NCI-H23 NGrxV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG3NkBp NGTMeGNFVVOR MXXJR|UxRTJwMkeg{txO NFLE[I0zOzV{MUCyNC=>
HCT116 M3nMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M336blczKGh? MkHqSG1UVw>? NX\sZlJVUUN3ME2yMlMh|ryP MUWyN|UzOTB{MB?=
MCF7 NHvLbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;mUmY4OiCq NWTkfG5QTE2VTx?= MW\JR|UxRTJwNUeg{txO MofINlM2OjFyMkC=
NCI-H460 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO3O|IhcA>? MWPEUXNQ MlrrTWM2OD16Lkm5JO69VQ>? MVqyN|UzOTB{MB?=
DLD1 NH71N|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS3NkBp M4jwZ2ROW09? MUnJR|UxRTRwNjFOwG0> M17zVFI{PTZ5OU[w
NCI-H661 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXzO|IhcA>? NFXZTVRFVVOR M{\nSWlEPTB;Nz64JO69VQ>? M4W3XFI{PTZ5OU[w
A549 Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTiO|IhcA>? M1\Lc2ROW09? MlKwTWM2OD16LkKg{txO NUDDbo9kOjN3Nke5OlA>
U937 NUnQbXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTvO|IhcA>? MWDEUXNQ NIfnZo1KSzVyPUGyMlIh|ryP MVGyN|U3Pzl4MB?=
HEK293 M{HERWZ2dmO2aX;uJGF{e2G7 MXqxNOKh|ryP MmiySG1UVw>? M2PjR2lv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ|zszN NVLVfFF{OjJ5N{C2NVA>
HUVEC MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2wMlE2yqEQvF2= MkPYO|IhcA>? NIPYeVlFVVOR NFnRZ|lKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> MmjrNlI5PTN7OUO=
HUVEC NUjDVXpPTnWwY4Tpc44hSXO|YYm= Mn;NNVXDqM7:TR?= MYS3NkBp NF;KNFZFVVOR MUTJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=> MXyyNlg2Ozl7Mx?=
Plasmodium falciparum NU[1U25rTnWwY4Tpc44hSXO|YYm= M1XrV|ExyqEQvF2= NU\NZZpsOTVibXnu NInrO2hFVVOR Mmn1TY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO Mom4NlQ2PTB|M{C=
PC3 NY[5T3BpTnWwY4Tpc44hSXO|YYm= MYOwMlEh|ryP MoDDOUBp NV7uRXhPTE2VTx?= NXPycld3UW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N MVexPVQ3Ojl5NR?=
DU145 NXLqZmIxTnWwY4Tpc44hSXO|YYm= MlK2NE4yKM7:TR?= Mn;5OUBp NILBdIxFVVOR NWDHWHY1UW6qaXLpeJMhcHWvYX6gSHUyPDViY3XscEBi\Ginc3nvckBifCBzMECgcm0> MkT5NVk1PjJ7N{W=
PC3 NF3scmVMcW6jc3WgRZN{[Xl? M2X5bFAvOSEQvF2= M{OwbFUhcA>? MV;EUXNQ M17QbGlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= M13QcVE6PDZ{OUe1
DU145 MXrLbY5ie2ViQYPzZZk> MoPDNE4yKM7:TR?= NHXUWFM2KGh? NVT4SHpGTE2VTx?= MojiTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N NEj3cJoyQTR4Mkm3OS=>
PC3 NYXkPY5sU2mwYYPlJGF{e2G7 Mm\PNE4yKM7:TR?= M17FZ|UhcA>? NYTScGFkTE2VTx?= NFzpeHFKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? MUGxPVQ3Ojl5NR?=
DU145 NYnmdJJSU2mwYYPlJGF{e2G7 M361SFAvOSEQvF2= NHLNVpo2KGh? M3Ta[2ROW09? MkjwTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? Ml\FNVk1PjJ7N{W=
Huh7 MVzBcpRqfmm{YXygRZN{[Xl? NXnNUIJTOi53IN88US=> MluxOEBl[Xm| NWHKZYJ3TE2VTx?= M33BfWlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NV7qO2V6OTd|NkC2O|Y>
C6/36 M13WXmFvfGm4aYLhcEBCe3OjeR?= M3HK[FIvPSEQvF2= M1zoOlQh\GG7cx?= NWnoSVVkTE2VTx?= MWfJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO NUXT[|VHOTd|NkC2O|Y>
U937 MXPGeY5kfGmxbjDBd5NigQ>? NUXCS4ZiOSEQvF2= M3LyRVEhcA>? M4jYWmROW09? M1O3TXJm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy| MmDONVc3QDRyOUm=
U937 M3rLUmZ2dmO2aX;uJGF{e2G7 MUCxJO69VQ>? NVHHcpo{OSCq MlO5SG1UVw>? M4LzfXJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{ M4jqXFE4Pjh2MEm5
murine mast cell NH7ie2lHfW6ldHnvckBCe3OjeR?= NED3e5kyKM7:TR?= M{fxfFI1KGh? M3yxRWROW09? MYHJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>? M{W5T|E4Pjh2MEm5
BV-173 NYnhUYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r5NWlEPTB;MD6wNFAxODBzMEmg{txO NXmyVnFZW0GQR1XS
K-562 MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMECwNFAxOjZ4IN88US=> MUPTRW5ITVJ?
BL-70 NVfVWYI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMECwNFAxQDJ{IN88US=> MWnTRW5ITVJ?
EM-2 NHfB[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7peXlKSzVyPUCuNFAxODBzMEig{txO NGHGclRUSU6JRWK=
LAMA-84 M3q4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMECwNFA{OjFizszN M2DsdHNCVkeHUh?=
MEG-01 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrxTWM2OD1yLkCwNFAxQThizszN MYrTRW5ITVJ?
EoL-1-cell MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMECwNFE{OSEQvF2= MoPxV2FPT0WU
CTV-1 NWXrdXd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMECwNFQxPCEQvF2= MojLV2FPT0WU
TE-15 MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITndG1KSzVyPUCuNFA2QDlizszN M2nxOHNCVkeHUh?=
NOS-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMEC2NVMh|ryP M17z[HNCVkeHUh?=
D-336MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;LUlRCUUN3ME2wMlAxPjNizszN MWrTRW5ITVJ?
LB1047-RCC M12wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzzeXVKSzVyPUCuNFA6QDlizszN Ml\KV2FPT0WU
LB996-RCC M1XOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vOZ2lEPTB;MD6wNFk6OSEQvF2= NHziUZlUSU6JRWK=
SW982 Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMEGxNVUh|ryP NH\VR5VUSU6JRWK=
TK10 NFHaRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmroTWM2OD1yLkCxNVc1KM7:TR?= NGjrN|dUSU6JRWK=
A704 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXkTWM2OD1yLkCxOFkyKM7:TR?= NYfSOpNxW0GQR1XS
TE-8 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TSemlEPTB;MD6wNVU4PiEQvF2= MWLTRW5ITVJ?
DOHH-2 M3LSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LwW2lEPTB;MD6wNVcyQSEQvF2= NUTWSoxKW0GQR1XS
HOP-62 MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHWTWM2OD1yLkCxPFM1KM7:TR?= M1\nS3NCVkeHUh?=
TE-12 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTBTWM2OD1yLkCxPFYyKM7:TR?= MkX2V2FPT0WU
KGN MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLWUnIxUUN3ME2wMlAyQTR{IN88US=> MX;TRW5ITVJ?
NCI-H1648 NGfUTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrUTWM2OD1yLkCyNFEyKM7:TR?= MUjTRW5ITVJ?
OS-RC-2 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMEKwN{DPxE1? M2jzOnNCVkeHUh?=
GB-1 M1z6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDtZnNlUUN3ME2wMlAzOTV5IN88US=> Mkj6V2FPT0WU
RXF393 NYrZUWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEKzOVch|ryP MYDTRW5ITVJ?
LC-2-ad MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[1TWM2OD1yLkCyOVg3KM7:TR?= M2nRZ3NCVkeHUh?=
KS-1 NF3GV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmniTWM2OD1yLkCyO|Mh|ryP M1\3bnNCVkeHUh?=
ETK-1 NHnGfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEK4N|Ih|ryP M{TrcXNCVkeHUh?=
SW954 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnqRWpKSzVyPUCuNFI6OjdizszN NFPic49USU6JRWK=
Becker MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrZ[HFKSzVyPUCuNFMxODNizszN NVLWOGhHW0GQR1XS
MZ1-PC MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLyOZI{UUN3ME2wMlA{OTF7IN88US=> M2XFe3NCVkeHUh?=
ES6 MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjlTWM2OD1yLkCzNVk{KM7:TR?= MV;TRW5ITVJ?
KURAMOCHI MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vQZmlEPTB;MD6wN|Q5PyEQvF2= M4PuPHNCVkeHUh?=
CGTH-W-1 NH72T5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XtcWlEPTB;MD6wN|U1QCEQvF2= NVuyT3llW0GQR1XS
VA-ES-BJ NVu1dnVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLiOXNtUUN3ME2wMlA{QTB{IN88US=> NHPZZXFUSU6JRWK=
LXF-289 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljDTWM2OD1yLkCzPVU3KM7:TR?= MYDTRW5ITVJ?
MPP-89 NXTwT2lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jIVmlEPTB;MD6wOFA1QSEQvF2= MX;TRW5ITVJ?
SW872 NUe3NlZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XJSGlEPTB;MD6wOFE3OSEQvF2= MnLZV2FPT0WU
SNB75 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTOTWM2OD1yLkC0OFM2KM7:TR?= NEPIdHNUSU6JRWK=
PSN1 NF71dZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPnU3lKSzVyPUCuNFQ1PzRizszN MWXTRW5ITVJ?
LB831-BLC MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrwSHBnUUN3ME2wMlA1PjB7IN88US=> NVv3clFlW0GQR1XS
MFH-ino NVKwdoNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMES3NlQh|ryP MoDlV2FPT0WU
TGBC24TKB MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[5TWM2OD1yLkC0O|YyKM7:TR?= NIHTZWpUSU6JRWK=
A388 NGXq[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIexbWZKSzVyPUCuNFUxQTVizszN NXjvVYtRW0GQR1XS
BB30-HNC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfQ[WlrUUN3ME2wMlA2PDN5IN88US=> NF;5bmhUSU6JRWK=
GI-ME-N NW\tTpExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rkcmlEPTB;MD6wOlEyQCEQvF2= MULTRW5ITVJ?
TGBC1TKB M4fq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\jUGlEPTB;MD6wOlE3PCEQvF2= NETLN2lUSU6JRWK=
TE-10 M2TGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jQfGlEPTB;MD6wOlM2PyEQvF2= M3rOeHNCVkeHUh?=
A498 M4nPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEeyPFQh|ryP MkLYV2FPT0WU
TE-11 NHWxbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j6e2lEPTB;MD6wO|g2QCEQvF2= M2jHUXNCVkeHUh?=
BB65-RCC NE\tT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor3TWM2OD1yLkC4NlI4KM7:TR?= NUnJcVFFW0GQR1XS
C2BBe1 M2HGVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLo[ZdYUUN3ME2wMlA5OzB6IN88US=> NYjtcIFkW0GQR1XS
NCI-H747 NVzLVZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHNPGJKSzVyPUCuNFg{PjJizszN M3PYbHNCVkeHUh?=
IST-MES1 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\N[ZVKSzVyPUCuNFg2PTJizszN NEfuTllUSU6JRWK=
KALS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[1eGlEPTB;MD6wPVQ6KM7:TR?= MonhV2FPT0WU
GCIY NIPJ[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMEm2OVYh|ryP NETiVZZUSU6JRWK=
RL95-2 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHrbG9KSzVyPUCuNVA{QCEQvF2= MmjTV2FPT0WU
TE-1 M4DP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMUC1OEDPxE1? MWnTRW5ITVJ?
NCI-H1355 MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7BTZVKSzVyPUCuNVExOjhizszN MUHTRW5ITVJ?
SW962 M2nte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fwTGlEPTB;MD6xNVI6OiEQvF2= MnvCV2FPT0WU
KLE M33DSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMUGzNVch|ryP NIjndXRUSU6JRWK=
MC116 NUPPfG54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\TUIVKSzVyPUCuNVE1OSEQvF2= M{DWWHNCVkeHUh?=
NMC-G1 M1e1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\hTWM2OD1yLkGxOlA3KM7:TR?= NYHmdopsW0GQR1XS
KU812 NIrJcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3TSocxUUN3ME2wMlEyQDh|IN88US=> MmW0V2FPT0WU
COLO-829 M4XWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCzTWM2OD1yLkGyNlE{KM7:TR?= Ml:1V2FPT0WU
NTERA-S-cl-D1 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HRdWlEPTB;MD6xNlI5OyEQvF2= NHraeWlUSU6JRWK=
IST-MEL1 M{Hjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELlSVhKSzVyPUCuNVM1PSEQvF2= MY\TRW5ITVJ?
MLMA MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF74eZFKSzVyPUCuNVQxOzJizszN M3nCbnNCVkeHUh?=
LS-123 Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrzOI57UUN3ME2wMlE1ODZ2IN88US=> NHnvZW1USU6JRWK=
LB2518-MEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMUSxOlIh|ryP NYHDcm9jW0GQR1XS
NB69 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID1b5RKSzVyPUCuNVQ1OzZizszN MVfTRW5ITVJ?
8-MG-BA NXG5N3U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe0UJBTUUN3ME2wMlE2PDV6IN88US=> M2ewOHNCVkeHUh?=
K5 NYnsXGZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LmNGlEPTB;MD6xOlQ5QSEQvF2= MoHLV2FPT0WU
KINGS-1 M{PGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnZZ3VKSzVyPUCuNVY3PjZizszN NUTk[4lbW0GQR1XS
SF268 NI[4TVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC4NYRKSzVyPUCuNVc1ODRizszN M3:wV3NCVkeHUh?=
PF-382 NWm1[lZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PuVGlEPTB;MD6xO|Y4QCEQvF2= MVXTRW5ITVJ?
SH-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXXTWM2OD1yLkG4OFE{KM7:TR?= M1HDdXNCVkeHUh?=
NALM-6 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jT[2lEPTB;MD6xPVI6PSEQvF2= MVHTRW5ITVJ?
CP66-MEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;oTWM2OD1yLkG5OVMyKM7:TR?= MULTRW5ITVJ?
697 NHu2OYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nKPWlEPTB;MD6xPVk5PyEQvF2= M1iwXHNCVkeHUh?=
CP67-MEL NGrkZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3juSmlEPTB;MD6yNFQ5QCEQvF2= M1;sTHNCVkeHUh?=
DSH1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n5W2lEPTB;MD6yOFAxOSEQvF2= M3;MNHNCVkeHUh?=
HCE-4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;sV2lEPTB;MD6yOlQ{QSEQvF2= NXnTPFczW0GQR1XS
MZ2-MEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D6WWlEPTB;MD6yPFU{PyEQvF2= M1W3OHNCVkeHUh?=
BL-41 M1rqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GyOWlEPTB;MD6yPVEzOyEQvF2= M2fhSnNCVkeHUh?=
HUTU-80 NFm5UlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO2fmRlUUN3ME2wMlMyPDJizszN NV3lXYtsW0GQR1XS
LOXIMVI NWmzXnJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwM{G1NFMh|ryP MYjTRW5ITVJ?
no-10 M{\Rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r0SmlEPTB;MD6zNVk{OSEQvF2= M2\3S3NCVkeHUh?=
KARPAS-422 NITaV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVruO2xOUUN3ME2wMlM{QTl5IN88US=> Mk\RV2FPT0WU
SW684 NH;3VZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwM{S5PEDPxE1? NVfzT4gzW0GQR1XS
SF126 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnOTlNZUUN3ME2wMlM2PDFizszN MoXWV2FPT0WU
D-263MG NVO5TVZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TZdmlEPTB;MD6zOlIzPCEQvF2= MX;TRW5ITVJ?
OVCAR-4 MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfQWZJGUUN3ME2wMlM4PDN|IN88US=> NXLhfZN1W0GQR1XS
BB49-HNC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[z[mlEPTB;MD6zPFU6QSEQvF2= M{DGPHNCVkeHUh?=
ONS-76 M1rpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwNEK5OVEh|ryP M3LNTHNCVkeHUh?=
MZ7-mel MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHizTpVKSzVyPUCuOFc6OTFizszN MVzTRW5ITVJ?
RCC10RGB NX33WIk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG2Z401UUN3ME2wMlQ6OTFizszN M{\N[HNCVkeHUh?=
BOKU M3uzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnRdYFNUUN3ME2wMlQ6OTN|IN88US=> M3TlXXNCVkeHUh?=
no-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXzSpRKSzVyPUCuOVAzOjhizszN MV7TRW5ITVJ?
IST-SL2 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwNUCzNFIh|ryP MVvTRW5ITVJ?
RKO NXv0bVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwNUK5OlYh|ryP M{XafnNCVkeHUh?=
HT-144 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\LTWM2OD1yLkWzOlA6KM7:TR?= NUPyV4hLW0GQR1XS
NCI-H446 MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwNkK3OkDPxE1? MmPjV2FPT0WU
QIMR-WIL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\iO3BKSzVyPUCuO|A3OjlizszN MmPsV2FPT0WU
MHH-PREB-1 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwN{S0Olkh|ryP M{nSOXNCVkeHUh?=
EW-16 M3vK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom3TWM2OD1yLke2NVc5KM7:TR?= NYTDN|czW0GQR1XS
EW-24 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XLfWlEPTB;MD63PFE3PSEQvF2= Mn;sV2FPT0WU
LB373-MEL-D NWTqOnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm3XVVKSzVyPUCuPFI2ODhizszN NGrQNY1USU6JRWK=
TE-9 NVrJUm9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HUemlEPTB;MD64O|U{OiEQvF2= M1r4[XNCVkeHUh?=
A3-KAW M4X2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLkdplKSzVyPUCuPVg1PTJizszN MlTsV2FPT0WU
A101D MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXMTWM2OD1zLkCzNFQ{KM7:TR?= Mo\IV2FPT0WU
OCUB-M MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwMES0NVIh|ryP NVTMR4p1W0GQR1XS
ES4 M13aOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HhWGlEPTB;MT6wOVE1PSEQvF2= MWLTRW5ITVJ?
TE-6 M4O2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7wTWM2OD1zLkKxNlI3KM7:TR?= MkT1V2FPT0WU
D-502MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwMkOzO|Yh|ryP MW\TRW5ITVJ?
KNS-42 MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\qbIVSUUN3ME2xMlI1PDF{IN88US=> Mm\WV2FPT0WU
SNU-C2B NGDmV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3mxfWlEPTB;MT6zNFU5QSEQvF2= M3jjVHNCVkeHUh?=
NCI-H1838 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\0TWM2OD1zLkOwO|M{KM7:TR?= M2jnNHNCVkeHUh?=
NKM-1 NFHuNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwM{C4OVkh|ryP Mn3SV2FPT0WU
GI-1 NEnpNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwM{[yNkDPxE1? MUjTRW5ITVJ?
NB5 M2q3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTlTWM2OD1zLkO5PFI4KM7:TR?= NVvHcpQ{W0GQR1XS
CAS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG3bXhKSzVyPUGuOFA6QTJizszN MUHTRW5ITVJ?
HCE-T MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3UdnMyUUN3ME2xMlU3PzF2IN88US=> M131Z3NCVkeHUh?=
SBC-1 NETzPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYexVZdoUUN3ME2xMlU4QTh2IN88US=> MUPTRW5ITVJ?
JiyoyeP-2003 M2e0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HkTWlEPTB;MT63N|Q3PiEQvF2= MVLTRW5ITVJ?
TE-5 M4\1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HUfWlEPTB;MT63PVE{QSEQvF2= M3\VXHNCVkeHUh?=
CAN M4fFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrVOnI{UUN3ME2xMlgzOjV{IN88US=> NIr4bXVUSU6JRWK=
SK-UT-1 NIr2cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Dn[GlEPTB;Mj6xOlY6OyEQvF2= NVyzOGJ3W0GQR1XS
JVM-2 NVHyUXo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPNWFRKSzVyPUKuN|YzQDRizszN NFPCN25USU6JRWK=
LB771-HNC M1L1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLSWWxwUUN3ME2yMlU4PTVzIN88US=> NEX4UpZUSU6JRWK=
NCCIT NGXhcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP6TWM2OD1{Lki2OlE3KM7:TR?= M3f2fHNCVkeHUh?=
NCI-H2126 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL4TWM2OD1{Lki3OVUzKM7:TR?= M3[xXHNCVkeHUh?=
Calu-6 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXXelNKSzVyPUOuNFU4PDFizszN NWXwToQ3W0GQR1XS
SK-LMS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjuNnpKSzVyPUOuNVE5QDZizszN M2DQXXNCVkeHUh?=
ARH-77 M124Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPUWo1KSzVyPUOuOFY6OTVizszN MVrTRW5ITVJ?
NB17 M1jONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T1OWlEPTB;Mz62N|g1PyEQvF2= M3v1NHNCVkeHUh?=
A253 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwN{OyOFYh|ryP NVP4WVZlW0GQR1XS
OPM-2 NFfvS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjFUoRKSzVyPUSuNlc3QDVizszN MkOwV2FPT0WU
MV-4-11 NGP5NlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfEVG5KSzVyPUSuN|Y1PTRizszN MVfTRW5ITVJ?
SR MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fVd2lEPTB;ND60PVk2PCEQvF2= NFi3b5BUSU6JRWK=
KG-1 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTRwNkC4OFUh|ryP MnH1V2FPT0WU
OCI-AML2 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTVwOE[xOVQh|ryP M1H3cXNCVkeHUh?=
D-247MG NWDJVZZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnETWM2OD14LkGyOVE6KM7:TR?= MYnTRW5ITVJ?
DJM-1 M3rT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTZwNEi1OVgh|ryP NGnBc4lUSU6JRWK=
RPMI-6666 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTdwMkewOlch|ryP M4LSXnNCVkeHUh?=
KARPAS-45 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13XeWlEPTB;Nz61NVY4OSEQvF2= MXvTRW5ITVJ?
LP-1 Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTdwNUS3PFIh|ryP MXLTRW5ITVJ?
RS4-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTaTWM2OD15Lk[1O|g4KM7:TR?= NXn3Nm9lW0GQR1XS
DU-4475 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fGfmlEPTB;OD6yNVY2OiEQvF2= MlLvV2FPT0WU
MONO-MAC-6 NH\aVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjQNYNKSzVyPUiuNlcxPjZizszN NGX1TlVUSU6JRWK=
NCI-SNU-16 NEnMSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe5[lRKSzVyPUiuOVYyOjhizszN MYTTRW5ITVJ?
SJSA-1 NYLhZ3JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W4PWlEPTB;OD63NlgxPSEQvF2= MX\TRW5ITVJ?
MMAC-SF MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDkTWM2OD16Lke5N|A4KM7:TR?= Mn3TV2FPT0WU
SK-NEP-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXSTWM2OD16Lki5NVU2KM7:TR?= NUfBU3R6W0GQR1XS
J-RT3-T3-5 M2nsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHznXndKSzVyPUiuPVY2OjlizszN Moj0V2FPT0WU
SKM-1 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PLWmlEPTB;OT6wNVc{PCEQvF2= MXzTRW5ITVJ?
LB2241-RCC NUPUS4lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTlwMEKwNVIh|ryP MX7TRW5ITVJ?
SIG-M5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTlwMEK0PVMh|ryP M1rY[HNCVkeHUh?=
EVSA-T MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTlwMke3PVMh|ryP MlH6V2FPT0WU
GT3TKB MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;YcJBKSzVyPUmuN|U2PDZizszN MVPTRW5ITVJ?
NB6 M3\GeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3vPI9KSzVyPUmuPVIzPTlizszN M374VHNCVkeHUh?=
EHEB NVLGfFVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFyLkC2OVYh|ryP MoDaV2FPT0WU
HEL NELOdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfYXJBKSzVyPUGwMlQ4PzZizszN Mn[5V2FPT0WU
ALL-PO NYrZUoE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rWPWlEPTB;MUCuO|k{QCEQvF2= MoT4V2FPT0WU
TGW MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuzTWM2OD1zMT6yPFI5KM7:TR?= NF\FeWpUSU6JRWK=
BC-3 NXXvPW5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPBSVFKSzVyPUGyMlEyOzhizszN MlW2V2FPT0WU
IA-LM NUDrSGdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHO[JJpUUN3ME2xNk41PDR3IN88US=> M2q0bHNCVkeHUh?=
UACC-257 NYnabIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DKUmlEPTB;MUKuPVE6QCEQvF2= NEH4bGFUSU6JRWK=
KP-N-YS MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF75XpZKSzVyPUGyMlkzQDNizszN MUfTRW5ITVJ?
Raji MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j6TWlEPTB;MUOuO|Q6PyEQvF2= M3LIVnNCVkeHUh?=
SF539 NVvCR|J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1iyemlEPTB;MUOuPFU2PyEQvF2= NFns[4lUSU6JRWK=
DMS-153 NUe1T49PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HINmlEPTB;MUSuNFAzQCEQvF2= M2P6PHNCVkeHUh?=
L-540 NXz0UJdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTGTWM2OD1zNT6wOlczKM7:TR?= MkPHV2FPT0WU
MN-60 NWLhRpRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF3LkG5O|kh|ryP MkDqV2FPT0WU
RPMI-8866 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF5LkS0OVQh|ryP Mn3uV2FPT0WU
NCI-H510A MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL2TWM2OD1zOT6zPVc{KM7:TR?= M3PkcHNCVkeHUh?=
NB13 M{DNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17kT2lEPTB;MUmuOFg4PyEQvF2= NYrkZodEW0GQR1XS
HAL-01 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF7Lke1OFMh|ryP MV3TRW5ITVJ?
NCI-H720 NXjKVVlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj6TWM2OD1{MD6yO|M{KM7:TR?= M323[nNCVkeHUh?=
REH MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJyLk[zOVch|ryP NEfwUGNUSU6JRWK=
KNS-81-FD MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnwTWM2OD1{Mz6xOFYh|ryP MVjTRW5ITVJ?
HC-1 M2rRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJ2LkW1OVEh|ryP M33RbnNCVkeHUh?=
NCI-H2141 MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXDPHVKSzVyPUK0Mlc4PTRizszN M3noUHNCVkeHUh?=
MOLT-4 NYDVZZVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PHV2lEPTB;Mk[uOlc2OyEQvF2= NYDzUYRiW0GQR1XS
OMC-1 NWLnWFkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17KXWlEPTB;MkeuNVQzOiEQvF2= MnfzV2FPT0WU
LC-1F NUS3V3hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO0VVIxUUN3ME2yO{4{OjR3IN88US=> MnPlV2FPT0WU
NCI-H1304 NUH4emVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3IO4JKSzVyPUK4MlE3OjhizszN Ml3RV2FPT0WU
BC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ6Lk[1NUDPxE1? NVfxdmp5W0GQR1XS
NCI-H64 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHyfJVPUUN3ME2yPU43OjV|IN88US=> MmC4V2FPT0WU
MOLT-16 NYTBboZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HTPGlEPTB;MkmuOlI6OiEQvF2= MVrTRW5ITVJ?
U-87-MG NXniclJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX6VlE5UUN3ME2zNE44PjZizszN MVjTRW5ITVJ?
GAK MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTNzLkK2PFYh|ryP NXGyZ4ZOW0GQR1XS
ES8 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPuTWM2OD1|Mj6xNlUzKM7:TR?= MmLzV2FPT0WU
HCC1599 NWPBOI1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13Ve2lEPTB;M{KuN|MzPSEQvF2= MnfGV2FPT0WU
EB-3 MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zjbmlEPTB;M{SuN|EyPyEQvF2= MnfWV2FPT0WU
HCC1187 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfTXIVKSzVyPUO1MlgxPTJizszN NWnoSW5VW0GQR1XS
SK-PN-DW NXewOnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm1NWhKSzVyPUO2MlE6PDNizszN MX\TRW5ITVJ?
JVM-3 MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[zTWM2OD1|Nz6yN|M5KM7:TR?= NUHO[4F[W0GQR1XS
HCC2157 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHvcYtKSzVyPUO3Mlk6PDZizszN NIrXUWxUSU6JRWK=
A4-Fuk MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDrbotGUUN3ME2zPE4yODB7IN88US=> M{PJU3NCVkeHUh?=
COR-L279 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTRyLkK4OVEh|ryP MVPTRW5ITVJ?
DEL NHewSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTEXpBKSzVyPUSxMlkxQDZizszN MVrTRW5ITVJ?
NCI-H1395 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC3TWM2OD12Mj6wNVY{KM7:TR?= M3nlRXNCVkeHUh?=
MHH-NB-11 M1m0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3kc5p4UUN3ME20N{4xQDF6IN88US=> NEnKSFJUSU6JRWK=
NCI-H2107 NEjlcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfuPYczUUN3ME20N{41QDR4IN88US=> M17o[3NCVkeHUh?=
NEC8 NXjOVm5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTR2LkOzOkDPxE1? MXnTRW5ITVJ?
COLO-684 M3O2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\RWGFCUUN3ME20Ok4zOjV6IN88US=> Mn25V2FPT0WU
LS-411N M2jWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX32T2xPUUN3ME20PE41PzR6IN88US=> NHvHfGJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Not yet recruiting Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC October 2018 Phase 2
NCT03516279 Not yet recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Minimal Residual Disease ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group August 12 2018 Phase 2
NCT03595917 Recruiting B-cell Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL Marlise R. Luskin|Novartis|Dana-Farber Cancer Institute July 24 2018 Phase 1
NCT03654768 Recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive Southwest Oncology Group|National Cancer Institute (NCI) July 20 2018 Phase 2
NCT03560908 Recruiting Relapsed AML|T(8;21)|C-KIT Mutation Institute of Hematology & Blood Diseases Hospital July 1 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products4

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID